Format
Sort by
Items per page

Send to

Choose Destination

Best matches for glutathione schizophrenia:

Search results

Items: 1 to 20 of 346

1.

Clozapine attenuates mitochondrial burdens and abnormal behaviors elicited by phencyclidine in mice via inhibition of p47 phox; Possible involvements of phosphoinositide 3-kinase/Akt signaling.

Tran HQ, Park SJ, Shin EJ, Tran TV, Sharma N, Lee YJ, Jeong JH, Jang CG, Kim DJ, Nabeshima T, Kim HC.

J Psychopharmacol. 2018 Sep 12:269881118795244. doi: 10.1177/0269881118795244. [Epub ahead of print]

PMID:
30207504
2.

Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione.

Das TK, Javadzadeh A, Dey A, Sabesan P, Théberge J, Radua J, Palaniyappan L.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Aug 17. pii: S0278-5846(18)30301-4. doi: 10.1016/j.pnpbp.2018.08.006. [Epub ahead of print] Review.

PMID:
30125624
3.

Metabolomics in patients with psychosis: A systematic review.

Li C, Wang A, Wang C, Ramamurthy J, Zhang E, Guadagno E, Trakadis Y.

Am J Med Genet B Neuropsychiatr Genet. 2018 Sep;177(6):580-588. doi: 10.1002/ajmg.b.32662. Epub 2018 Aug 4. Review.

PMID:
30076730
4.

Probable mechanisms involved in the antipsychotic-like activity of morin in mice.

Ben-Azu B, Aderibigbe AO, Omogbiya IA, Ajayi AM, Owoeye O, Olonode ET, Iwalewa EO.

Biomed Pharmacother. 2018 Sep;105:1079-1090. doi: 10.1016/j.biopha.2018.06.057. Epub 2018 Jun 20.

PMID:
30021344
5.

Protective effects of Spinacia oleracea seeds extract in an experimental model of schizophrenia: Possible behavior, biochemical, neurochemical and cellular alterations.

Yadav M, Parle M, Sharma N, Jindal DK, Bhidhasra A, Dhingra MS, Kumar A, Dhingra S.

Biomed Pharmacother. 2018 Sep;105:1015-1025. doi: 10.1016/j.biopha.2018.06.043. Epub 2018 Jun 19.

PMID:
30021336
6.

The sinister face of heme oxygenase-1 in brain aging and disease.

Schipper HM, Song W, Tavitian A, Cressatti M.

Prog Neurobiol. 2018 Jul 28. pii: S0301-0082(18)30055-8. doi: 10.1016/j.pneurobio.2018.06.008. [Epub ahead of print] Review.

PMID:
30009872
7.

Role of Novel Dietary Supplement N-acetyl Cysteine in Treating Negative Symptoms in Schizophrenia: A 6-Month Follow-up Study.

Tharoor H, Mara S, Gopal S.

Indian J Psychol Med. 2018 Mar-Apr;40(2):139-142. doi: 10.4103/IJPSYM.IJPSYM_322_17.

8.

Morin Attenuates Neurochemical Changes and Increased Oxidative/Nitrergic Stress in Brains of Mice Exposed to Ketamine: Prevention and Reversal of Schizophrenia-Like Symptoms.

Ben-Azu B, Aderibigbe AO, Eneni AO, Ajayi AM, Umukoro S, Iwalewa EO.

Neurochem Res. 2018 Sep;43(9):1745-1755. doi: 10.1007/s11064-018-2590-z. Epub 2018 Jun 28.

PMID:
29956036
9.

Glutathione and glutamate in schizophrenia: a 7T MRS study.

Kumar J, Liddle EB, Fernandes CC, Palaniyappan L, Hall EL, Robson SE, Simmonite M, Fiesal J, Katshu MZ, Qureshi A, Skelton M, Christodoulou NG, Brookes MJ, Morris PG, Liddle PF.

Mol Psychiatry. 2018 Jun 22. doi: 10.1038/s41380-018-0104-7. [Epub ahead of print]

PMID:
29934548
10.

NMDA-receptor inhibition and oxidative stress during hippocampal maturation differentially alter parvalbumin expression and gamma-band activity.

Hasam-Henderson LA, Gotti GC, Mishto M, Klisch C, Gerevich Z, Geiger JRP, Kovács R.

Sci Rep. 2018 Jun 22;8(1):9545. doi: 10.1038/s41598-018-27830-2. Erratum in: Sci Rep. 2018 Aug 29;8(1):13170.

11.

Sulforaphane Augments Glutathione and Influences Brain Metabolites in Human Subjects: A Clinical Pilot Study.

Sedlak TW, Nucifora LG, Koga M, Shaffer LS, Higgs C, Tanaka T, Wang AM, Coughlin JM, Barker PB, Fahey JW, Sawa A.

Mol Neuropsychiatry. 2018 May;3(4):214-222. doi: 10.1159/000487639. Epub 2018 Apr 17.

PMID:
29888232
12.

Improvement of cognitive function in schizophrenia with N-acetylcysteine: A theoretical review.

Yolland COB, Phillipou A, Castle DJ, Neill E, Hughes ME, Galletly C, Smith ZM, Francis PS, Dean OM, Sarris J, Siskind D, Harris AWF, Rossell SL.

Nutr Neurosci. 2018 May 30:1-10. doi: 10.1080/1028415X.2018.1478766. [Epub ahead of print]

PMID:
29847303
13.

Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study.

Hafizi S, Da Silva T, Meyer JH, Kiang M, Houle S, Remington G, Prce I, Wilson AA, Rusjan PM, Sailasuta N, Mizrahi R.

Neuropsychopharmacology. 2018 Apr 13. doi: 10.1038/s41386-018-0061-5. [Epub ahead of print]

PMID:
29748630
14.

Alterations in oxidative stress markers and its correlation with clinical findings in schizophrenic patients consuming perphenazine, clozapine and risperidone.

Hendouei N, Farnia S, Mohseni F, Salehi A, Bagheri M, Shadfar F, Barzegar F, Hoseini SD, Charati JY, Shaki F.

Biomed Pharmacother. 2018 Jul;103:965-972. doi: 10.1016/j.biopha.2018.04.109. Epub 2018 Apr 25.

PMID:
29710513
15.

Mitochondrial function in individuals at clinical high risk for psychosis.

Da Silva T, Wu A, Laksono I, Prce I, Maheandiran M, Kiang M, Andreazza AC, Mizrahi R.

Sci Rep. 2018 Apr 18;8(1):6216. doi: 10.1038/s41598-018-24355-6.

16.

Glutathione, the Major Redox Regulator, in the Prefrontal Cortex of Individuals at Clinical High Risk for Psychosis.

Da Silva T, Hafizi S, Andreazza AC, Kiang M, Bagby RM, Navas E, Laksono I, Truong P, Gerritsen C, Prce I, Sailasuta N, Mizrahi R.

Int J Neuropsychopharmacol. 2018 Apr 1;21(4):311-318. doi: 10.1093/ijnp/pyx094.

17.

Adjunctive nutrients in first-episode psychosis: A systematic review of efficacy, tolerability and neurobiological mechanisms.

Firth J, Rosenbaum S, Ward PB, Curtis J, Teasdale SB, Yung AR, Sarris J.

Early Interv Psychiatry. 2018 Oct;12(5):774-783. doi: 10.1111/eip.12544. Epub 2018 Mar 21. Review.

PMID:
29561067
18.

N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis.

Conus P, Seidman LJ, Fournier M, Xin L, Cleusix M, Baumann PS, Ferrari C, Cousins A, Alameda L, Gholam-Rezaee M, Golay P, Jenni R, Woo TW, Keshavan MS, Eap CB, Wojcik J, Cuenod M, Buclin T, Gruetter R, Do KQ.

Schizophr Bull. 2018 Feb 15;44(2):317-327. doi: 10.1093/schbul/sbx093.

19.

Doxycycline prevents and reverses schizophrenic-like behaviors induced by ketamine in mice via modulation of oxidative, nitrergic and cholinergic pathways.

Ben-Azu B, Omogbiya IA, Aderibigbe AO, Umukoro S, Ajayi AM, Iwalewa EO.

Brain Res Bull. 2018 May;139:114-124. doi: 10.1016/j.brainresbull.2018.02.007. Epub 2018 Feb 6.

PMID:
29425796

Supplemental Content

Loading ...
Support Center